Frank J Wolters1, Renée F A G de Bruijn1, Albert Hofman1, Peter J Koudstaal1, M Arfan Ikram2. 1. From the Departments of Neurology (F.J.W., R.F.A.G.d.B., P.J.K., M.A.I.), Epidemiology (F.J.W., R.F.A.G.d.B., A.H., M.A.I.), and Radiology (M.A.I.), Erasmus Medical Centre, Rotterdam, The Netherlands. 2. From the Departments of Neurology (F.J.W., R.F.A.G.d.B., P.J.K., M.A.I.), Epidemiology (F.J.W., R.F.A.G.d.B., A.H., M.A.I.), and Radiology (M.A.I.), Erasmus Medical Centre, Rotterdam, The Netherlands. m.a.ikram@erasmusmc.nl.
Abstract
OBJECTIVE: Cerebral vasoreactivity (CVR) is a key factor in maintenance of continuous cerebral perfusion and a marker of (micro)vascular damage. We aimed to determine the longitudinal relation between CVR and the risk of dementia in the general population. APPROACH AND RESULTS: We determined CVR in nondemented participants who underwent transcranial Doppler with induced hypercapnia from 1997 to 1999, as part of the ongoing population-based Rotterdam Study. We used a Cox model to determine the risk of dementia in relation to CVR, adjusted for age, sex, cardiovascular risk factors, and carotid intima-media thickness. We furthermore determined decline on a cognitive test battery in relation to CVR, using linear mixed models. Among 1629 participants (mean ± SD age 70.6 ± 6.2 years, 46.2% female) with a mean follow-up of 11.5 years, 209 were diagnosed with dementia, of whom 171 had Alzheimer disease. Higher CVR at baseline was associated with lower risk of dementia (adjusted hazard ratio, 95% confidence interval, per SD increase: 0.87, 0.75-1.00) and Alzheimer disease (adjusted hazard ratio, 0.84; 0.71-0.99). This association was more profound in APOEε4 carriers than in noncarriers (adjusted hazard ratio for all dementia: 0.77, 0.60-0.98 versus 0.89, 0.73-1.07). Performance on cognitive tests at baseline was better with higher CVR (g-factor: P=0.02), but during 3 cognitive assessments over 11 years of follow-up, higher CVR at baseline was associated with less decline in test scores on the Stroop reading and interference tasks in APOEε4 carriers only (P=0.01 and 0.02, respectively). CONCLUSIONS: Impaired CVR is associated with an increased risk of dementia in the general population.
OBJECTIVE: Cerebral vasoreactivity (CVR) is a key factor in maintenance of continuous cerebral perfusion and a marker of (micro)vascular damage. We aimed to determine the longitudinal relation between CVR and the risk of dementia in the general population. APPROACH AND RESULTS: We determined CVR in nondemented participants who underwent transcranial Doppler with induced hypercapnia from 1997 to 1999, as part of the ongoing population-based Rotterdam Study. We used a Cox model to determine the risk of dementia in relation to CVR, adjusted for age, sex, cardiovascular risk factors, and carotid intima-media thickness. We furthermore determined decline on a cognitive test battery in relation to CVR, using linear mixed models. Among 1629 participants (mean ± SD age 70.6 ± 6.2 years, 46.2% female) with a mean follow-up of 11.5 years, 209 were diagnosed with dementia, of whom 171 had Alzheimer disease. Higher CVR at baseline was associated with lower risk of dementia (adjusted hazard ratio, 95% confidence interval, per SD increase: 0.87, 0.75-1.00) and Alzheimer disease (adjusted hazard ratio, 0.84; 0.71-0.99). This association was more profound in APOEε4 carriers than in noncarriers (adjusted hazard ratio for all dementia: 0.77, 0.60-0.98 versus 0.89, 0.73-1.07). Performance on cognitive tests at baseline was better with higher CVR (g-factor: P=0.02), but during 3 cognitive assessments over 11 years of follow-up, higher CVR at baseline was associated with less decline in test scores on the Stroop reading and interference tasks in APOEε4 carriers only (P=0.01 and 0.02, respectively). CONCLUSIONS: Impaired CVR is associated with an increased risk of dementia in the general population.
Authors: Sana Suri; Daniel Bulte; Scott T Chiesa; Klaus P Ebmeier; Peter Jezzard; Sebastian W Rieger; Jemma E Pitt; Ludovica Griffanti; Thomas W Okell; Martin Craig; Michael A Chappell; Nicholas P Blockley; Mika Kivimäki; Archana Singh-Manoux; Ashraf W Khir; Alun D Hughes; John E Deanfield; Daria E A Jensen; Sebastian F Green; Veronika Sigutova; Michelle G Jansen; Enikő Zsoldos; Clare E Mackay Journal: Front Physiol Date: 2021-03-31 Impact factor: 4.566
Authors: Frank J Wolters; Francesco U S Mattace-Raso; Peter J Koudstaal; Albert Hofman; M Arfan Ikram Journal: PLoS Med Date: 2016-10-11 Impact factor: 11.069
Authors: Anna E Leeuwis; Lorna A Smith; Andrew Melbourne; Alun D Hughes; Marcus Richards; Niels D Prins; Magdalena Sokolska; David Atkinson; Therese Tillin; Hans R Jäger; Nish Chaturvedi; Wiesje M van der Flier; Frederik Barkhof Journal: Front Aging Neurosci Date: 2018-09-18 Impact factor: 5.750
Authors: Fernando Gongora-Rivera; Adolfo Cordero-Perez; Alejandro Gonzalez-Aquines; Antonio Anaya-Escamilla; Eduardo Villarreal-Garza; Meztli Espinosa-Ortega; Mario C Salinas-Carmona; Xochilt Ortiz-Jimenez Journal: Int J Alzheimers Dis Date: 2018-09-09
Authors: Lana Fani; Oscar Roa Dueñas; Daniel Bos; Meike W Vernooij; Caroline C W Klaver; M Kamran Ikram; Robin P Peeters; M Arfan Ikram; Layal Chaker Journal: J Clin Endocrinol Metab Date: 2022-02-17 Impact factor: 6.134
Authors: Abrar M Babateen; Oliver M Shannon; Gerard M O'Brien; Edward Okello; Ellen Smith; Dilara Olgacer; Christina Koehl; William Fostier; Emma Wightman; David Kennedy; John C Mathers; Mario Siervo Journal: Nutrients Date: 2022-03-02 Impact factor: 5.717
Authors: Lidia Glodzik; Henry Rusinek; Tracy Butler; Yi Li; Pippa Storey; Elizabeth Sweeney; Ricardo S Osorio; Adrienne Biskaduros; Emily Tanzi; Patrick Harvey; Christopher Woldstad; Thomas Maloney; Mony J de Leon Journal: Front Aging Neurosci Date: 2022-09-07 Impact factor: 5.702